Christopher Twitty

CIK: 0001870121

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)7 (53.8%)

Compensation grants

Other (G, F, J, C, D, …)6 (46.2%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

SKYE

Skye Bioscience, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (13 total)

SKYE
Skye Bioscience, Inc.
Mar 31, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
12K shares-
SKYE
Skye Bioscience, Inc.
Mar 31, 2026
Award(A)
Stock Option (Right to Buy)
Direct
17K shares-
SKYE
Skye Bioscience, Inc.
Mar 31, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
17K shares-
SKYE
Skye Bioscience, Inc.
Mar 31, 2026
Award(A)
Stock Option (Right to Buy)
Direct
75K shares-
SKYE
Skye Bioscience, Inc.
Mar 31, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
75K shares-
SKYE
Skye Bioscience, Inc.
Mar 31, 2026
Award(A)
Stock Option (Right to Buy)
Direct
7.1K shares-
SKYE
Skye Bioscience, Inc.
Mar 31, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
7.1K shares-
SKYE
Skye Bioscience, Inc.
Mar 31, 2026
Award(A)
Stock Option (Right to Buy)
Direct
200K shares-
SKYE
Skye Bioscience, Inc.
Mar 31, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
200K shares-
SKYE
Skye Bioscience, Inc.
Mar 31, 2026
Award(A)
Stock Option (Right to Buy)
Direct
150K shares-
SKYE
Skye Bioscience, Inc.
Mar 31, 2026
Disposition(D)
Stock Option (Right to Buy)
Direct
150K shares-
SKYE
Skye Bioscience, Inc.
Mar 31, 2026
Award(A)
Stock Option (Right to Buy)
Direct
12K shares-
SKYE
Skye Bioscience, Inc.
Feb 6, 2026
Award(A)
Stock Option (Right to Buy)
Direct
150K shares-

		Type	Shares	Price		Ownership
Mar 31, 2026	SKYE Skye Bioscience, Inc.	Disposition(D) Stock Option (Right to Buy)	12,000	-	-	Direct
Mar 31, 2026	SKYE Skye Bioscience, Inc.	Award(A) Stock Option (Right to Buy)	17,004	-	-	Direct
Mar 31, 2026	SKYE Skye Bioscience, Inc.	Disposition(D) Stock Option (Right to Buy)	17,004	-	-	Direct
Mar 31, 2026	SKYE Skye Bioscience, Inc.	Award(A) Stock Option (Right to Buy)	75,000	-	-	Direct
Mar 31, 2026	SKYE Skye Bioscience, Inc.	Disposition(D) Stock Option (Right to Buy)	75,000	-	-	Direct
Mar 31, 2026	SKYE Skye Bioscience, Inc.	Award(A) Stock Option (Right to Buy)	7,100	-	-	Direct
Mar 31, 2026	SKYE Skye Bioscience, Inc.	Disposition(D) Stock Option (Right to Buy)	7,100	-	-	Direct
Mar 31, 2026	SKYE Skye Bioscience, Inc.	Award(A) Stock Option (Right to Buy)	200,000	-	-	Direct
Mar 31, 2026	SKYE Skye Bioscience, Inc.	Disposition(D) Stock Option (Right to Buy)	200,000	-	-	Direct
Mar 31, 2026	SKYE Skye Bioscience, Inc.	Award(A) Stock Option (Right to Buy)	150,000	-	-	Direct
Mar 31, 2026	SKYE Skye Bioscience, Inc.	Disposition(D) Stock Option (Right to Buy)	150,000	-	-	Direct
Mar 31, 2026	SKYE Skye Bioscience, Inc.	Award(A) Stock Option (Right to Buy)	12,000	-	-	Direct
Feb 6, 2026	SKYE Skye Bioscience, Inc.	Award(A) Stock Option (Right to Buy)	150,000	-	-	Direct

1-13 of 13 transactions

About Twitty Christopher

Twitty Christopher (SEC CIK 0001870121) files insider reports with the SEC as Chief Scientific Officer of Skye Bioscience, Inc. (SKYE).

Signal8 holds 3 ownership filings by Twitty Christopher (1 Form 3, 2 Form 4), filed between Apr 25, 2025 and Apr 2, 2026. Those filings report 13 transactions, from Feb 6, 2026 to Mar 31, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Twitty Christopher's filings is in SAN DIEGO, CA.

Recent filings by Twitty Christopher

Mar 31, 2026: Disposition to issuer transaction of SKYE derivative securities (Form 4, code D).
Mar 31, 2026: Grant or award of SKYE derivative securities (Form 4, code A).
Mar 31, 2026: Disposition to issuer transaction of SKYE derivative securities (Form 4, code D).
Mar 31, 2026: Grant or award of SKYE derivative securities (Form 4, code A).
Mar 31, 2026: Disposition to issuer transaction of SKYE derivative securities (Form 4, code D).

Other insiders filing for Skye Bioscience, Inc. (SKYE)

Schwab Andrew J., Director
5AM Partners VII, LLC, 10% Owner
DHILLON PUNIT, Chief Executive Officer
Sharp John P, Chief Financial Officer
Smith Karen L., Director
Jenkins Annalisa, Director

How to read Form 4 transaction codes